TITLE:
Lethargic Depression Study

CONDITION:
Epilepsy

INTERVENTION:
Extended-release bupropion (HCl)

SUMMARY:

      This is a study of Major Depressive Disorder (MDD) in patients with decreased energy,
      pleasure and interests.
    

DETAILED DESCRIPTION:

      A Multicenter, Double-Blind, Placebo-controlled comparison of the efficacy and safety of
      flexible dose extended-release bupropion (HCl) 300-450 mg/day and placebo administered for
      eight weeks for the treatment of adult outpatients with major depressive disorder including
      symptoms of decreased energy, pleasure, and interest
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion criteria:

          -  Primary diagnosis of MDD with current duration lasting 12 weeks but no greater than 2
             years.

          -  Generally in good health.

          -  Subject must read and write at a level sufficient to provide written informed
             consent.

        Exclusion criteria:

          -  Current or past history of seizure disorder.

          -  Subject has a primary diagnosis or received treatment for panic disorder, obsessive
             compulsive disorder (OCD), post traumatic stress disorder (PTSD), acute stress
             disorder, Bipolar I or II disorder, schizophrenia, or other psychotic disorder.

          -  Currently using illicit drugs or other psychotropic drugs.

          -  Patient poses a current suicidal risk or has attempted suicide in the past 6 months.
      
